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Abstract
Introduction: The excess of adipose tissue in obese individuals may have immunomodulating properties and
pharmacokinetic consequences. The aim of this study was to determine whether body mass index (BMI) affects
response to infliximab (IFX) in ankylosing spondylitis (AS) patients.
Methods: In 155 patients retrospectively included with active AS, the BMI was calculated before initiation of IFX
treatment (5 mg/kg intravenously). After 6 months of treatment, changes from baseline in BASDAI, Visual Analogue
Scale (VAS) pain, C-reactive protein (CRP) level, and total dose of nonsteroidal antiinflammatory drug (NSAID) were
dichotomized with a threshold corresponding to a decrease of 50% of initial level of the measure, into binary
variables assessing response to IFX (BASDAI50, VAS50, CRP50, NSAID50). Whether the BMI was predictive of the
response to IFX therapy according to these definitions was assessed with logistic regression.
Results: Multivariate analysis found that a higher BMI was associated with a lower response for BASDAI50 (P =
0.0003; OR, 0.87; 95% CI (0.81 to 0.94)), VAS50 (P < 0.0001; OR, 0.87; 95% CI (0.80 to 0.93)); CRP50 (P = 0.0279; OR,
0.93; 95% CI (0.88 to 0.99)), and NSAID50 (P = 0.0077; OR, 0.91; 95% CI (0.85 to 0.97)), criteria. According to the
three WHO BMI categories, similar results were found for BASDAI50 (77.6%, 48.9%, and 26.5%; P < 0.0001), VAS50
(72.6%, 40.4%, and 16.7%; P < 0.0001); CRP50 (87.5%, 65.7%, and 38.5%; P = 0.0001), and NSAID50 (63.2%, 51.5%,
and 34.6%; P = 0.06).
Conclusions: This study provides the first evidence that a high BMI negatively influences the response to IFX in
AS. Further prospective studies, including assessment of the fat mass, pharmacokinetics, and adipokines dosages
are mandatory to elucidate the role of obesity in AS IFX response.
Introduction
Overweight and obesity are defined as abnormal or
excessive fat accumulation that presents a risk to health
[1]. A crude population measure of obesity is the body
mass index (BMI). Individuals with a BMI of 30 kg/m2
or more are considered obese.
It is now well known that pharmacokinetic variables of
drug clearance and volume of distribution (Vd) could be
influenced by overweight and obesity [2]. In addition,
adipose tissue can exert both endocrine and immune
effects on multiple other organs through the release of
adipocytokines [3], which are suspected to contribute to
the pathogenesis of several inflammatory conditions,
including rheumatoid arthritis (RA) [4]. Even if to date
and to our knowledge, the role of fat tissue has not
been widely investigated in ankylosing spondylitis (AS),
several indirect results suggest a possible link between
the AS-related inflammation and fat tissue excess: (a)
weight loss and subsequent lower BMI are linked to a
high RA activity [5]; and (b) a significant increase in
body weight and fat mass has been observed in AS
patients receiving anti-tumor necrosis factor (TNF)-a
treatment [6].
In addition to its potential implication in the inflam-
matory process of rheumatic conditions, a recent report
has suggested that fat mass may also affect the response
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to therapy by showing a negative correlation between
BMI and response to infliximab (IFX) in RA [7]. Indeed,
the authors observed that RA patients with a high BMI
responded less well to IFX, a finding that held true
when adjusted for the baseline DAS28 or anti-citrulli-
nated protein antibody status [7]. Hence, those results
led to the hypothesis that BMI could be considered a
new predictive marker of IFX response in inflammatory
diseases, including at least RA. With regard to the criti-
cal issue that remains, the identification of predictors to
biologics, we aimed to investigate whether the BMI
could influence the IFX response in AS.
Materials and methods
Study population
We performed a retrospective study including 155 con-
secutive individuals fulfilling the European Spondyloar-
thropathy Study Group (ESSG) AS criteria [8], who have
received or receive infliximab. All patients had active
AS, according to the Assessment of SpondyloArthritis
Society (ASAS) criteria [9]. Participating centers were
the Rheumatology A Department of Cochin hospital
and the Rheumatology Department of Bichat Hospital,
Paris, France. The following data were collected at base-
line (M0) and at month 6 (M6) for the analysis: BMI,
gender, age, disease duration, Bath Ankylosing Spondyli-
tis Disease Activity Index (BASDAI), pain visual analo-
gue scale (VAS), use of nonsteroidal antiinflammatory
drugs (NSAIDs), HLA B27 status, and C-reactive protein
(CRP) level. BMI was calculated by weight in kilograms
divided by height in square meters at baseline and M6.
According to the WHO criteria, normal BMI was
defined as a BMI < 25 kg/m2; overweight, as a BMI of
25 to 30 kg/m2; and obesity, as a BMI > 30 kg/m2 [1].
The baseline demographic and clinical features of the
AS patients are summarized in Table 1. Infliximab was
given intravenously at 5 mg/kg every 6 weeks, according
to international recommendations [9].
Clinical response was assessed after 6 months of IFX
therapy. For each of these criteria, change from baseline
was dichotomized, with a threshold corresponding to a
decrease of 50% of the initial level of the measure, into
binary variables corresponding to different definitions of
response to IFX (that is, BASDAI50, VAS50, CRP50,
and NSAID50). The BASDAI20 and BASDAI70 also
were assessed. No specific recommendation was made
regarding the use of NSAIDs according to the IFX
response.
The study was approved by the local institutional
review board (Number 11-089), and written informed
consent was obtained from all subjects in the study.
Statistical analysis
Continuous variables are expressed as mean (SD) or
median (IQR). Categoric variables are expressed as fre-
quencies and percentages. Comparisons between catego-
ric variables were performed by using the Pearson c2
test. The Student t test (two-tailed) was used to com-
pare normally distributed continuous variables, and the
Wilcoxon rank-sum test for continuous variables not
normally distributed.
To determine predictors of the response to IFX
according to the different definitions of this response
(BASDAI20, BASDAI50, BASDAI70, VAS50, CRP50,
and NSAID50), we fitted logistic regressions. We
included in the first models all variables significantly
associated with each dependant variable in univariate
analyses to a P level of 0.20. BMI was considered as a
continuous variable in the multivariate analyses.
Several methods were implemented to select the vari-
ables to include in the final models (forward, backward,
and stepwise). Indexes of goodness-to-fit were
Table 1 Baseline characteristics of 155 AS patients according to the three WHO BMI categories
Whole AS population
(n = 155)
BMI < 25 kg/m2
(n = 63)
BMI [25-30] kg/m2
(n = 54)
BMI > 30 kg/m2
(n = 38)
P value
Age (years), median [IQR] 43.1 [35.0-51.8] 38.5 [31.6-48.6] 45.0 [35.6-52.6] 45.4 [40.0-50.0] 0.0127
Male gender, n (%) 98 (63.3) 45 (71.4) 36 (66.6) 17 (44.7) 0.0214
HLAB27, n (%) 96 (64.9) 48 (76.2) 28 (57.1) 20 (55.6) 0.0451
Disease duration (years),
median [IQR]
8.0 [3.0-12.0] 8.0 [4.0-12.0] 7.0 [3.0-11.0] 6.0 [3.0-12.0] 0.7640
BASDAI
(0 to -100 mm), median [IQR]
60.0 [47.5-70.0] 60.0 [50.0-73.0] 56.0 [48.0-66.0] 62.0 [34.0-70.0] 0.4782
VAS pain
(0 to 100 mm), median [IQR]
61.0 [50.0-75.0] 65.0 [50.0-80.0] 60.0 [50.0-70.0] 70.0 [49.0-75.0] 0.4598
Use of NSAIDs
(% of maximal dose), mean (SD)
62.2 (45.7) 72.2 (42.9) 53.7 (42.9) 57.4 (46.0) 0.0703
CRP (mg/dl), median [IQR] 10.0 [5.0-24.0] 11.0 [5.0-23.0] 14.0 [5.0-33.0] 7.9 [5.0-16.0] 0.2550
AS, Ankylosing spondylitis; BASDAI; Bath ankylosing spondylitis disease activity index; BMI, body mass index; CRP, C-reactive protein; IQR, interquartile range
NSAID, nonsteroidal antiinflammatory drugs; VAS, visual analogue scale.
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calculated, as the AUC and Hosmer and Lemeshow test.
The AIC index also was calculated at each step.
To investigate further whether the BMI influenced the
BASDAI response criteria 6 months after initiation of
IFX therapy, we plotted each of the BASDAI response
criteria according to BMI considered in three levels (<
25 kg/m2; 25 to 30 kg/m2; and > 30 kg/m2).
Statistical analysis was performed by using SAS soft-
ware version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Characteristics of ankylosing spondylitis patients at
baseline
During the 6-month period reported here, two patients
stopped the IFX therapy: one for lack of response, and
one for infectious pneumonitis. At month 6, among the
155 AS patients consecutively included, the BASDAI
response was not available for 14 of them.
In accordance with the WHO definition [1], distribu-
tion of individuals having normal weight, overweight,
and obesity was 41%, 35%, and 24%, respectively. Char-
acteristics of the three BMI populations are summarized
in Table 1. Age (P = 0.0127), male gender (P = 0.0214),
and HLAB27-positive status (P = 0.0451) at baseline
were significantly different across the three BMI groups.
Other characteristics showed no significant differences
(Table 1). No difference was noted for the characteris-
tics of AS patients between the two participating centers
(data not shown)
For all multivariate models, all methods implemented
to select variables to include in the final models (for-
ward, backward, and both) proposed the same final
models.
BMI is associated with a lower rate of response to
infliximab in ankylosing spondylitis after 6 months of
therapy, according to the BASDAI
After 6 months of IFX therapy, 55.4% of AS patients
achieved the BASDAI50 response. Univariate analysis
found an association between several factors and nonre-
sponse to IFX at M6: BMI (P < 0.0001), female gender
(P = 0.0102), and age at inclusion (P = 0.0469) (Table
2). Conversely, BASDAI50 responders were found to
have a high level of CRP compared with nonresponders
(P = 0.0039). Additionally, the HLAB27-positive status
was found to be more frequent in the BASDAI50-
responder subgroup (P = 0.047; Table 2).
We next investigated whether the BMI at inclusion,
according to the three WHO BMI categories, could
influence the BASDAI response after 6 months of IFX
therapy. We observed a strong decrease of the propor-
tion of responders in normal to overweight and obese
AS patients: 77.6%, 48.9%, and 26.5%, respectively (P <
0.0001) (Figure 1).
Interestingly, a significant linear decrease of frequency
of BASDAI20 responders according to the three BMI
categories also was observed: 84.5%, 70.2%, and 41.2%,
respectively (P < 0.0001). When the BASDAI70 was
queried, similar results were observed: 48.3%, 29.8%, and
5.9% (P < 0.0001), respectively (Figure 1). When analysis
was dichotomized according to the gender, a significant
decrease of BASDAI20 (P = 0.0011), BASDAI50 (P =
0.002), and BASDAI70 (P = 0.0055) responses were
observed only in male patients.
Multivariate analysis, including gender, identified both
baseline BMI and CRP level as independent factors pre-
dictive of the BASDAI50 response at month 6: P =
0.0003; OR, 0.87; 95% CI (0.81 to 0.94); and P = 0.0448;
OR, 1.02; and 95% CI (1.00 to 1.04), respectively. Linear
regression analysis found a strong correlation between
the ∆BASDAI and BMI (P <0.0001; b = 1.30).
BMI is associated with a lower rate of response to
infliximab in ankylosing spondylitis after 6 months of
therapy, according to VAS50, CRP50, and NSAID50
When analysis was performed according to the three
BMI categories, we observed a decrease in the propor-
tion of VAS50 responders: 72.6%, 40.4%, and 16.7%,
respectively (P < 0.0001) (Figure 1). The proportion of
CRP50 responders was 87.5% in normal weight, 65.7%
in overweight, and 38.5% in obese AS patients (P =
0.0001) (Figure 1). In good agreement with the distribu-
tion of both VAS50 and CRP50 responses according to
the three BMI categories, a linear decrease of proportion
of NSAID50 responders also was observed, but not
reaching statistical significance: 63.2%, 51.5%, and 34.6%,
respectively (P = 0.06) (Figure 1). According to the gen-
der, a significant decrease of VAS50 (P = 0.0002) and
Table 2 Baseline characteristics of the ankylosing
spondylitis patients treated with infliximab according to
the response BASDAI50 after 6 months of infliximab
Yes
(n = 77)a
No
(n = 62)a
P
value
Age (years), median (IQR) 39.4 (32.0
-50.0)
44.8 (38.2-
53.0)
0.0469
Gender (% males) 72.7 51.6 0.0102
Disease duration (years), median
(IQR)
8.0 (4.0-14.0) 6.0 (3.0-12.0) 0.1966
BMI (kg/m2) 24.4 (21.9-
26.8)
28.7 (25.6-
31.6)
<
0.0001
HLAB27 (% of patients) 73.3 56.9 0.0470
∆weight (kg), median (IQR) -1.0 (-2.0-2.0) 0.0 (-2.0-3.0) 0.4948
Baseline CRP (mg/dl), median
(IQR)
14.0 (5.0-
26.0)
6.6 (3.0-13.0) 0.0039
aTwo patients withdrew from IFX therapy (lack of response and serious
adverse event) and BASDAI50 lacking data for 14 AS patients
BASDAI50, 50% improvement in the Bath Ankylosing Spondylitis Disease
Activity Index; BMI, body mass index; CRP, C-reactive protein; IQR, interquartile
range.
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CRP50 (P = 0.0007) responses was detected in male
patients. In female AS patients, only the VAS50
response was decreased, reaching statistical significance
(P = 0.005).
Multivariate analysis identified a higher BMI and male
gender as independent factors associated with the
VAS50 response: OR, 0.87; 95% CI (0.80 to 0.93); P <
0.0001; and OR, 2.11; 95% CI (1.01 to 4.41); P = 0.0461,
respectively (Table 3).
Regarding the CRP50 response, multivariate analysis
found a higher BMI and high CRP level at baseline as pre-
dictive of the CRP50 response: OR, 0.93; 95% CI (0.88 to
0.99); P = 0.0279; and OR, 1.03; 95% CI (1.01 to 1.05); P =
0.0022, respectively (Table 3). A higher BMI was found to
be negatively associated with the NSAID50 response: OR,
0.91; 95% CI (0.85 to 0.97); P = 0.0077 (Table 3).
Discussion
The excess of adipose tissue in obese individuals may
have immunomodulating properties and pharmacoki-
netics consequences [2]. In this study, we investigated
retrospectively whether the BMI could influence the
response to IFX in AS patients. Of most interest,
although the baseline BASDAI was found to be similar
in the three BMI categories of AS individuals (that is,
normal, overweight, and obese), multivariate analysis,
including gender, identified the BMI as an independent
risk factor for a poor response at M6, whatever the
response criteria considered (BASDAI50, VAS50,
CRP50, or NSAID50). In good agreement with this find-
ing, when BASDAI20, 50, and 70 responses were quer-
ied according to the three WHO BMI categories, a
higher BMI resulted in a decrease of clinical response to
IFX in the whole AS population (Figure 1). However,
when analyses were performed according to gender,
similar results were observed in both male and female
populations, reaching statistical significance only in AS
male patients. Nevertheless, the multivariate analysis,
including gender as covariate, provides evidence for an
independent role of BMI in the IFX response, ruling out
a residual confounding by gender.
Figure 1 Clinical response and body mass index (BMI) in ankylosing spondylitis (AS) patients after 6 months of treatment with
infliximab, according to the three WHO BMI categories. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein;
NSAIDs, nonsteroidal antiinflammatory drugs; VAS, visual analogue scale.
Table 3 Response criteria influenced by BMI identified
through multivariate analysis: a higher BMI is
independently associated with a nonresponse of
ankylosing spondyloarthritis to infliximab at month 6a
Response criteria P value OR (95% CI]a
BASDAI50 0.0003 0.87 (0.81-0.94)
VAS50 < 0.0001 0.87 (0.80-0.93)
CRP50 0.0279 0.93 (0.88-0.99)
NSAID50 0.0077 0.91 (0.85-0.97)
aAdjusted on significant factors in univariate analysis (P < 0.20). BASDAI, Bath
ankylosing spondylitis disease activity index; CRP, C-reactive protein; NSAIDs,
nonsteroidal antiinflammatory drugs; VAS, visual analogue scale.
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Both lower BMI and high CRP level at baseline were
found to be associated with a good response to IFX.
Interestingly, a recent study reported that a high CRP
level was associated with a good outcome in AS [10,11].
Nonetheless, in these studies, the BMI was not assessed
[10,11]. In addition, and to strengthen the independent
role of BMI as a predictive marker of the IFX response,
it is of note that, in our study, baseline CRP was not dif-
ferent among the three BMI categories (Table 1).
To our knowledge, this is the first reported study
investigating the influence of BMI on the response to
IFX in AS. Of most interest, similar results were
observed in RA patients treated with IFX, as a signifi-
cant association between a low BMI and the decrease in
the DAS28 after 16 weeks was observed [7]. Addition-
ally, it is now well established that obesity is associated
with psoriasis [12]. Interestingly, a previous cohort study
reported a decrease of response to systemic agents in
psoriasis [13]. A negative impact of weight was also
found with ustekinumab and etanercept [14]. However,
other studies revealed that BMI did not influence the
response to IFX in psoriasis [14,15]. If IFX therapy was
found to be associated with a gain of weight, in Crohn
disease (CD), to date, no study designed to investigate
the role of BMI in modulating the response to IFX is
available [16,17]. Most interestingly, a recent study
found that CD patients with a low baseline BMI (< 18.5)
and those with small-bowel involvement achieved a
higher increase in BMI as compared with patients with
BMI ≥18.5 or patients without small-bowel involvement
[17]. These findings suggest that fat-tissue excess could
play a role in modulating the response to anti-TNF-a in
RA, AS, psoriasis, and CD.
The rate of response in our study was found to be
49.6% for BASDAI50, which is in line with previous
reports [18,19]. Of the most interest, 77.6% of AS
patients who were of normal weight achieved the BAS-
DAI50 response compared with 26.5% of obese patients.
Hence, obesity should be considered a predictor factor
of low-rate response to IFX in AS, leading to a threefold
decrease of the response rate.
Although IFX had a dose fixed according to the
patient’s weight, huge variations of interindividual serum
concentration have been widely reported in different
inflammatory diseases [20,21]. Unlike that observed in
RA [20], treatment failure was not associated with a low
circulation concentration of IFX in AS [21]. Further
pharmacokinetic findings could explain the negative
influence of a high BMI on the IFX response. The
volume of distribution, Vd, of a drug provides an esti-
mate of the extent to which a drug is distributed into
extravascular tissues. A wide variation exists in the effect
on the Vd, because the affinity of each drug for the
excess adipose tissue is unique. Hence, a nonlipophilic
drug, such as IFX, whose distribution into the excess
adipose tissue is limited, could alter the Vd [2]. In addi-
tion, tissue blood flow influences drug distribution. Tis-
sue perfusion and cardiac function may be reduced in
obese individuals, leading to a decrease of IFX distribu-
tion [22].
A direct role of the fat tissue excess through the
release of adipocytokines may also contribute to predict-
ing drug response. Nonetheless, the putative influence
of IFX therapy on adipocytokines production in AS
remains unclear. IFX therapy was reported to increase
weight and fat mass in the first 6 months of treatment
in AS patients [6]. Conversely, another study failed to
detect any association between IFX therapy and leptin
serum-level variation [23]. Taking into account that (a)
TNF-a induces cachexia and (b) a lower weight is corre-
lated with active RA [5], it could be hypothesized that
IFX good responders are more likely to have a TNF-a-
driven disease, leading to a lower BMI. Nonetheless,
caution should be taken with the hypothesis about a
direct role of fat tissue-related mediators in AS, as to
date, this remains speculative, and robust data are
lacking.
Taking into account the increasing number of obese
patients worldwide, investigation of the consequences of
an excess of fat mass on drug metabolism is not trivial.
Further studies have shown a direct influence of obesity
on drug pharmacokinetics, notably regarding che-
motherapy [24] and antihypertensive drugs [25,26]. Con-
sequently, clearly a need exists for further work in
elucidating the complex mechanisms involved in the
development of obesity-associated resistance to IFX.
This study has some limitations. The design of our
study was retrospective, which can lead to different
biases, notably, the lack of pharmacokinetics analyses
including correlation study between the IFX clearance
and BMI. Additionally, we did not have detailed data on
concurrent drugs that could be related to the over-
weight/obese status, and, therefore, are unable to assess
the impact of the therapies on the results. However,
regarding the BMI, similar findings were recently
reported in a study in RA, and preliminary prospective
data, not yet published, support our conclusions [27].
BMI is an indirect measure of body composition. Hence,
a direct quantification of the body fat mass and fat-free
mass should be assessed by using skinfold measurement,
bioelectrical impedance analysis, or dual-energy x-ray
absorptiometry to understand better the effect of each
tissue in pharmacokinetics and adipocytokine
production.
Conclusion
In conclusion, with very recent data observed in RA, we
provide the first evidence that a higher BMI negatively
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influences the response to IFX in AS. Further prospec-
tive studies are now required to determine how this
must be taken into account for the treatment of RA and
AS patients with IFX and probably other biologic agents.
In addition, more data, including more-precise assess-
ment of the fat mass, adipocytokines release, and phar-
macokinetic study of the drug, are needed to elucidate
the mechanism by which fat mass affects response to
IFX in inflammatory rheumatic conditions.
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